First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases
Crossref DOI link: https://doi.org/10.1007/s00228-017-2205-7
Published Online: 2017-02-04
Published Print: 2017-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Helmer, Eric
Watling, Mark
Jones, Emma
Tytgat, Dominique
Jones, Mark
Allen, Rodger
Payne, Andrew
Koch, Annelize
Healy, Eugene
Funding for this research was provided by:
UCB Pharma
License valid from 2017-02-04